ISG
6.2.2024 15:01:33 CET | Business Wire | Press release
With the threat of recession still looming, two-thirds of European insurance industry leaders plan to expedite their digitalization programs to improve the customer journey and enhance operational efficiencies, according to new survey research from Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm.
The ISG "Pulse Check - State of the European Insurance Industry" survey, conducted in the fourth quarter of 2023, surveyed nearly 270 business decision-makers and IT leaders in the European insurance industry and found 66 percent plan to increase their digital investments in the next two years, including 68 percent who say they will invest in payment channels, 63 percent each in cybersecurity and augmented and virtual reality, and 59 percent in artificial intelligence.
Survey participants said their two main strategic priorities are acquiring new customers, identified as a top priority by 85 percent of respondents, and leveraging digital channels to develop new business opportunities (74 percent). Increased investments in digital offerings and personalized customer services will help drive customer acquisition and retention, the ISG report noted.
"’Digital first’ is the focus as European insurers implement next-generation technologies that promise the quickest return on investment for their core businesses and to improve their market position,” said Steve Hall, president of ISG EMEA and the firm’s chief AI officer. "Process and decision automation and data management will help create human-centered, technology-enabled businesses that leverage rapidly evolving digital technology to reshape work, lower costs and improve service. AI will undoubtedly be an additional accelerator.”
The survey found demand for artificial intelligence (AI) is experiencing particularly strong growth. Thirteen percent of respondents report their annual budget for AI is already set at more than €1 million, and six out of ten expect to receive additional funding in 2024. Enterprises indicate they plan to leverage large language models alongside established AI methods such as natural language processing and machine learning.
AI development is still at an early stage for many respondents, with half of companies (50 percent) experimenting with prototypes and only 6 percent actively developing enterprise-wide AI solutions. Eighteen percent of respondents say technologies such as augmented reality (AR) and virtual reality (VR) are being used to reduce business insurance losses through preventive maintenance.
Ninety-one percent of respondents consider improving the effectiveness of customer data management a critical investment priority. Data silos remain a challenge, with only about one-fifth of existing customer data being effectively utilized, according to the ISG research.
Cybersecurity is another area of focus as enterprises increasingly rely on digital infrastructure that may expose assets to business interruption and cyber-attacks. Investments in digital risk management will continue to increase, particularly in cybersecurity and AI, to offer “customer trust” as a key differentiator and meet increasing regulations. Sixty-three percent of respondents expect their cybersecurity budgets to increase between 2024 and 2026 in response to escalating risks and regulatory demands.
"Insurers are prioritizing investments in AI, legacy modernization and IT security. Strategic partnerships can increase access to digital capabilities, process knowledge and specialized talent while expanding market access and sharing development risk,” Hall added. "The share of organizations that see consolidation of their service provider portfolio as a top IT priority is growing significantly, from 59 percent in 2022 to 93 percent in 2023.”
Striking a balance between insourcing and outsourcing is critical given the evolving dynamics of the labor market and the need to attract and retain IT talent, the report said. The percent of survey respondents who plan to invest in insourcing (78 percent) is almost the same as the number who plan to invest in outsourcing (77 percent). Sixty-eight percent of decision-makers see improving talent management as a pressing business imperative.
"As tech companies and insurtech startups become more attractive employers for young, tech-savvy talent, traditional carriers are challenged to attract and retain top talent," Hall concluded. "High-quality talent management is becoming a critical factor in meeting transformative technology demands."
The ISG "Pulse Check – State of European Insurance Industry 2024” report is available for download on this website.
About ISG
ISG (Information Services Group) (Nasdaq: III) is a leading global technology research and advisory firm. A trusted business partner to more than 900 clients, including more than 75 of the world’s top 100 enterprises, ISG is committed to helping corporations, public sector organizations, and service and technology providers achieve operational excellence and faster growth. The firm specializes in digital transformation services, including automation, cloud and data analytics; sourcing advisory; managed governance and risk services; network carrier services; strategy and operations design; change management; market intelligence and technology research and analysis. Founded in 2006, and based in Stamford, Conn., ISG employs more than 1,600 digital-ready professionals operating in more than 20 countries—a global team known for its innovative thinking, market influence, deep industry and technology expertise, and world-class research and analytical capabilities based on the industry’s most comprehensive marketplace data. For more information, visit www.isg-one.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206423163/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
